Merrill Upgrades Guidant to 'Buy'

Analyst Daniel Lemaitre likes the medical-device maker's deal to co-promote Cypher drug stents

Merrill Lynch upgraded Guidant (GDT ) to buy from neutral.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.